-+ 0.00%
-+ 0.00%
-+ 0.00%

BLUEPRINT MEDICINES ANNOUNCES DATA REINFORCING SUSTAINED CLINICAL EFFICACY AND WELL-TOLERATED SAFETY PROFILE OF LONG-TERM AYVAKIT®/AYVAKYT® (AVAPRITINIB) TREATMENT AT 2025 EHA AND EAACI CONGRESSES

Reuters·06/12/2025 22:01:03

Please log in to view news